期刊文献+

渐进性抗阻训练联合普拉克索治疗改善帕金森病患者肌张力 被引量:21

Progressive Resistance Training Combined with Pramipexole Therapy for Improving Muscular Tension in Patients with Parkinson's Disease
下载PDF
导出
摘要 目的:探讨普拉克索联合渐进性抗阻训练对帕金森病患者肌张力的疗效。方法:选取帕金森病患者125例,随机分为对照组45例、抗阻训练组40例、帕金森操组40例,3组均给予普拉克索药物治疗,抗阻训练组和帕金森操组还分别给予抗阻训练和帕金森操康复。对3组患者分别在不同随访时间点进行帕金森评分量表(UPDRS)、帕金森病Webster评分量表及Berg平衡量表进行评分;同时使用改良的Ashworth量表评价肌张力的变化水平。结果:3组中,抗阻训练组的UPDRS得分最高(P<0.05),抗阻训练组和帕金森操组的随访UPDRS得分逐渐增高(P<0.05)。3组4个时间点的Berg平衡量表得分、Webster症状评分入组时最高,随访18月水平最低(P<0.05);随访3月、12月和18月的得分均可见差异有统计学意义,抗阻训练组得分最低(P<0.05)。抗阻训练组和对照组各有1例嗜睡和1例恶心患者。3组4个时间点的Ashworth量表评分差异均有统计学意义,入组时最高,随访18月最低(均P<0.05),随访3月、12月和18月的Ashworth量表评分均可见差异有统计学意义,抗阻训练组得分最低,对照组得分最高(P<0.05)。结论:普拉克索联合渐进性抗阻训练对于改善帕金森病患者肌张力的效果优于普拉克索联合帕金森操的干预效果和单纯使用普拉克索药物治疗的效果。 Objective: To discuss the effect of Pramipexole combined with progressive resistance training on improving muscular tension in patients with Parkinson’s disease. Methods: Total 125 patients with Parkinson’s disease were enrolled and were randomly divided into groups control (n=45), anti-resistance training (n=40) and Parkinson’s exercise (n=40). All the groups were treated with Pramipexole. The anti-resistance training group and the Parkinson’s exercise group were also given resistance training and Parkinson’s exercise rehabilitation, respectively.The Parkinson’s Rating Scale (UPDRS), the Parkinson’s Disease Webster Scale and the Berg Balance Scale were used to evaluate at different time points. The modified Ashworth scale was used to evaluate the change in muscular tension. Results: Among the 3 groups, the UPDRS scores were the highest in the anti-resistance training group (P<0.05), and the UPDRS scores in the anti-resistance training and the Parkinson’s group were gradually increased during the follow-up period (P<0.05). Among the four time points, the Berg balance scale score and Webster symptom score of the three groups were the highest at the time of enrollment, and the lowest at the 18 months follow-up (P<0.05). The scores of 3 months, 12 months and 18 months of follow-up were all different with statistical significance, and the anti-resistance training group had the lowest score (P< 0.05). There was 1 case of sleepiness and 1 case of nausea in the anti-resistance training group and the control group, respectively. There were significant differences in the Ashworth scale scores between the 3 groups at 4 time points, and the scores were the highest at the time of enrollment and the lowest at the 18 months follow-up (P<0.05). The Ashworth scale scores of the follow-up 3 months, 12 months, and 18 months were statistically significant, with the lowest scores in the anti-resistance training group and the highest in the control group (P<0.05). Conclusion: The effect of Pramipexole combined with progressive resistance training on improving muscular tension in patients with Parkinson’s disease is better than that of Pramipexole combined with Parkinson’s exercise and Pramipexole alone.
作者 沈骏 侍永伟 鞠强国 姜宇 王继升 袁颖 徐建红 周仁华 SHEN Jun;SHI Yong-wei;JU Qiang-guo;JIANG Yu;WANG Ji-sheng;YUAN Ying;XU Jian-hong;ZHOU Ren-hua(Department of Neurology, The Fourth Hospital of Taizhou, Jiangsu 225300, China)
出处 《神经损伤与功能重建》 2019年第3期124-127,共4页 Neural Injury and Functional Reconstruction
基金 泰州市科技支撑计划(社会发展项目 No.SSF20150124)
关键词 普拉克索 渐进性抗阻训练 帕金森操 帕金森病 肌张力 Pramipexole progressive resistance training Parkinson's exercise Parkinson's disease muscle tension
  • 相关文献

参考文献12

二级参考文献121

  • 1陆晓红,于明,朱颖,吴旭明,王璇,冷闻辉.依达拉奉对阿尔茨海默病模型大鼠海马神经元凋亡的影响[J].江苏大学学报(医学版),2011,21(3):194-198. 被引量:3
  • 2蒋雨平,王坚,丁正同,邬剑军,陈嬿.原发性帕金森病的诊断标准(2005年)[J].中国临床神经科学,2006,14(1):40-40. 被引量:156
  • 3武力勇,贾建平.普拉克索的临床应用及安全性[J].药物不良反应杂志,2007,9(2):77-80. 被引量:20
  • 4WaltersA S,LeBrocq C,Dhar A,et al.Validation of the inte-mational restless legs syndrome study group ratingscale for restless legs syn-drome[J].Sleep Med,2003,4(2):121-132.
  • 5Kushida CA.Pramipexole for the treatment of restless legs syn-drome[J].Expertopin Pharmacother,2006,7(4):441-451.
  • 6陈海波,王新德.统一帕金森病评定量表[J].中华老年医学杂志,1999,18(1):61-62.
  • 7Lees A J, Hardy J, Revesz T. Parkinson "s disease. Lancet, 2009,373 : 2055 - 2066.
  • 8Goldman SM. Environmental toxins and Parkinson- disease. Annu Rev Pharmacol Toxicol, 2014,54 : 141 - 164.
  • 9Gautier CA, Corti O, Brice A. Mitochondrial dysfunctions in Parkinson- disease. Rev Neurol (Paris) , 2014,170 : 339 343.
  • 10Papa S, De Rasmo D. Complex I deficiencies in neurologicaldisorders. Trends Mol Med, 2013,19 : 61 -69.

共引文献158

同被引文献199

引证文献21

二级引证文献120

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部